Decision guide for radioactive iodine treatment in intermediate-risk thyroid cancer
Official title: Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer: The Radiance Trial
Run by Georgetown University · NCT06980103 · Data updated 2026-11-12
This study tests whether a web-based decision aid helps adults newly diagnosed with intermediate-risk differentiated thyroid cancer decide about radioactive iodine treatment, compared with standard American Cancer Society information.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 408 (estimated) |
| Sponsor | Georgetown University Academic / other |
| Locations | 3 sites (Washington D.C., District of Columbia and 2 other locations) |
| Status | Recruiting |
| Started | August 6, 2025 |
| Main results expected | February 28, 2029 |
| Study ends | July 31, 2029 |
| Registry record updated | January 8, 2026 |
| Trial ID | NCT06980103 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) diagnosed within the past six months with intermediate‑risk differentiated thyroid cancer who are deciding about RAI, able to consent and use web-based materials, and without prior RAI or contraindications are ideal candidates.
✕Probably not a fit
Patients with low‑risk or high‑risk disease, prior RAI treatment, clinical contraindications to RAI (for example pregnancy or lactation), or inability to use web-based tools are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized study enrolls adults diagnosed within the past six months with intermediate-risk differentiated thyroid cancer who are facing the decision about radioactive iodine (RAI) treatment. Participants are randomly assigned to view a tailored web-based decision aid (RAI Decisions) with videos, expandable details, values clarification exercises, and question-preparation tools, or to receive standard educational material from the American Cancer Society website. The study measures participants' understanding of RAI risks and benefits, whether choices align with individual values, and overall decision quality. Results will compare informed, values‑concordant decision-making between the decision aid and usual care groups.
Why it matters
Potential benefit: If successful, the decision aid could help patients better understand the risks and benefits of RAI and make treatment choices that match their priorities, potentially avoiding unnecessary treatment.
How similar studies have gone: Decision aids in other cancer treatment decisions have improved patient knowledge and decision quality, but RAI-specific decision aids for intermediate‑risk thyroid cancer are relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 and older * Patients diagnosed with intermediate risk DTC \< 6 months ago and who are making a decision about RAI treatment * Ability to understand the information conveyed in the informed consent form, pose questions and process answers (e.g., no cognitive impairment per direct consultation with the patient's physician), and, finally, provided informed consent to participate. * Participants willingness to be contacted and remain available to complete study activities throughout the duration of the study. Exclusion Criteria: * Diagnosis of low risk or high risk DTC * Prior history of RAI * Clinical contraindications that prevent consideration of RAI (e.g., pregnancy, lactation, neutropenia if considering high dose of RAI)
Where it's running
-
Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States Recruiting -
MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States Recruiting -
Inova Health System
Falls Church, Virginia, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer
In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.
-
Selective coverage radiotherapy vs. full coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer
This trial tests whether covering only the tumor-affected area with radiation is as effective as full-area coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer, while aiming to reduce side effects and improve quality of life.
-
Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer
This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).
-
WeChat-supported neck exercises after thyroidectomy
A telehealth program using a WeChat mini program tests if guided neck exercises after thyroid surgery help early recovery and quality of life.
-
Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors
This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.
-
AI chatbot to guide thyroid cancer patients through perioperative education
A new AI chatbot is being tested to see if it helps thyroid cancer patients better prepare for discharge, recover well, and stay engaged in their care compared with traditional education.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.